Target-specific immunoPET Imaging of Breast Cancer

Recruiting now · Phase 1/Phase 2

Conditions studied: Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic

In brief

The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.

Key facts

Study ID

NCT06715826

Run by

RenJi Hospital

People needed

200

Starts

2024-09-21

Expected to finish

2026-11-01

Last updated by the study team

2026-01-27

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18-75 years old and of female gender；
• Histologically confirmed diagnosis of breast cancer or suspected breast cancer by diagnostic imaging;
• Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.

You may not qualify if…

• Pregnancy；
• Severe hepatic and renal insufficiency;
• History of serious surgery in the last month;
• Allergic to antibody or single-domain antibody radiopharmaceuticals.

Where it is running

• Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.